Innovent and IASO Bio Announce Strategic Collaboration on BCMA CAR-T Therapy and Equity Investment
IASO Biotechnology
Cancer Treatment New Drug Developer
Innovent
High-end Biologics Developer
▎WuXi AppTec Content Team Report
July 5th update: IASO Bio and Innovent Bio jointly announced that they have signed a series of cooperation agreements. According to the terms of the agreement, IASO Bio will purchase relevant rights owned by Innovent Bio under the original BCMA CAR-T cooperation agreement at an agreed price; meanwhile, Innovent Bio will invest in IASO Bio at the same price.Will hold 18% of IASO Bio's shares after the investment.。
Under the new strategic cooperation framework, the two parties will achieve a high degree of resource integration in the field of cellular immunotherapy. IASO Bio will obtain the injection of Equecabtagene Autoleucel.Global Market Commercialization Rights, and independently responsible for and make decisions on the development, production, and sales of the products; meanwhile, Innovent Bio becomes a strategic shareholder of IASO Bio.
According to the press release, the Ixazomib Injection jointly developed by IASO Bio and Innovent Bio was officially approved for marketing by China's National Medical Products Administration (NMPA) on June 30, 2023, for the treatment ofMultiple MyelomaIn March 2024, its new drug clinical trial application (IND) was approved again, intending to expand the indications for the treatment of previous...Patients with relapsed/refractory multiple myeloma who have received 1-2 prior lines of therapy and are lenalidomide-resistant. In 2024, its treatment for refractoryGeneralized Myasthenia Gravis (gMG) and other autoimmune diseasesNew drug clinical trial applications (IND) in the field have also been approved in both China and the United States.
References:
[1] IASO BioInnovent Bio Deepens Strategic Cooperation to Jointly Promote Innovative Development in the Field of Cell Therapy Drugs. Retrieved July 5 , 2024, from https://mp.weixin.qq.com/s/CqyKKxgD2MEJtsB0Je-xHw
[2] Innovent Bio Deepens Strategic Cooperation with IASO Bio, Jointly Promoting Innovation and Development in the Field of Cell Therapy Drugs Retrieved July 5 , 2024, from https://mp.weixin.qq.com/s/-sDJmrP2RmlqbDPg3clTBQ
This article was compiled and edited by the WuXi AppTec content team based on publicly available information. Feel free to share it on your personal social media feeds. For authorization to repost, please leave a message on the "MedView" WeChat Official Account to contact us. For other collaboration inquiries, please reach out to wuxi_media@wuxiapptec.com.
Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it imply that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.
